leadf
logo-loader
viewUrigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

Urigen Pharmaceuticals, Inc CEO Dan Vickery sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The privately-held company specializes in non-oncological urology treatments.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FenixOro Gold continues aggressive drill program at their Abriaqui Project...

FenixOro Gold (CSE: FENX-OTCQB: FDVXF) CEO John Carlesso joined Steve Darling from Proactive to bring details about their drilling program that is ongoing at their gold silver and copper project in Colombia. That project is called Abriaqui and sits along a very mineralized belt. Carlesso...

7 hours, 25 minutes ago

2 min read